@prefix dcterms: <http://purl.org/dc/terms/> .
@prefix this: <http://www.tkuhn.ch/bel2nanopub/RAQBJapIuUCMsOG8XIDCcpA4R45XRblRPbQx2Kzq5hutk> .
@prefix sub: <http://www.tkuhn.ch/bel2nanopub/RAQBJapIuUCMsOG8XIDCcpA4R45XRblRPbQx2Kzq5hutk#> .
@prefix beldoc: <http://resource.belframework.org/belframework/20131211/knowledge/large_corpus.bel> .
@prefix rdfs: <http://www.w3.org/2000/01/rdf-schema#> .
@prefix rdf: <http://www.w3.org/1999/02/22-rdf-syntax-ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .
@prefix dce: <http://purl.org/dc/elements/1.1/> .
@prefix pav: <http://purl.org/pav/> .
@prefix np: <http://www.nanopub.org/nschema#> .
@prefix belv: <http://www.selventa.com/vocabulary/> .
@prefix prov: <http://www.w3.org/ns/prov#> .
@prefix chebi: <http://www.ebi.ac.uk/chebi/searchId.do?chebiId=> .
@prefix schem: <http://resource.belframework.org/belframework/20131211/namespace/selventa-legacy-chemicals/> .
@prefix obo: <http://purl.obolibrary.org/obo/> .
@prefix occursIn: <http://purl.obolibrary.org/obo/BFO_0000066> .
@prefix species: <http://www.ncbi.nlm.nih.gov/Taxonomy/Browser/wwwtax.cgi?id=> .
@prefix pubmed: <http://www.ncbi.nlm.nih.gov/pubmed/> .
@prefix orcid: <http://orcid.org/> .
sub:Head {
   this: np:hasAssertion sub:assertion ;
    np:hasProvenance sub:provenance ;
    np:hasPublicationInfo sub:pubinfo ;
    a np:Nanopublication .
}
sub:assertion {
   sub:_1 occursIn: obo:CL_0000169 , obo:UBERON_0001969 , species:9606 ;
    rdf:object schem:Triacylglycerol ;
    rdf:predicate belv:decreases ;
    rdf:subject chebi:6801 ;
    a rdf:Statement .
  sub:assertion rdfs:label "a(CHEBI:metformin) -| a(SCHEM:Triacylglycerol)" .
}
sub:provenance {
   beldoc: dce:description "Approximately 61,000 statements." ;
    dce:rights "Copyright (c) 2011-2012, Selventa. All rights reserved." ;
    dce:title "BEL Framework Large Corpus Document" ;
    pav:authoredBy sub:_3 ;
    pav:version "20131211" .
  sub:_2 prov:value "When used as monotherapy or with a sulfonylurea, metformin decreases plasma triglyceride and low-density lipoprotein (LDL) cholesterol levels by 10% to 15% (14, 90-92, 106) (Table 1), reduces postprandial hyperlipemia (14), decreases plasma free fatty acid levels, and decreases free fatty acid oxidation (14, 106, 107)." ;
    prov:wasQuotedFrom pubmed:10454950 .
  sub:_3 rdfs:label "Selventa" .
  sub:assertion prov:hadPrimarySource pubmed:10454950 ;
    prov:wasDerivedFrom beldoc: , sub:_2 .
}
sub:pubinfo {
   this: dcterms:created "2014-07-03T14:31:31.664+02:00"^^xsd:dateTime ;
    pav:createdBy orcid:0000-0001-6818-334X , orcid:0000-0002-1267-0234 .
}